The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gene Editing for CEP290 -Associated Retinal Degeneration
Open accessAbstract
Background CEP290 -associated inherited retinal degeneration causes severe early-onset vision loss due to pathogenic variants in CEP290 . EDIT-101 is a clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) gene-editing complex designed to treat inherited retinal degeneration caused by a specific damaging variant in intron 26 of CEP290 (IVS26 variant). Methods We performed a phase 1–2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290 -associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye. The primary outcome was safety, which included adverse events and dose-limiting toxic effects. Key secondary efficacy outcomes were the change from baseline in the best corrected visual acuity, the retinal sensitivity detected with the use of full-field stimulus testing (FST), the score on the Ora–Visual Navigation Challenge mobility test, and the vision-related quality-of-life score on the National Eye Institute Visual Function Questionnaire–25 (in adults) or the Children’s Visual Function Questionnaire (in children). Results EDIT-101 was injected in 12 adults 17 to 63 years of age (median, 37 years) at a low dose (in 2 participants), an intermediate dose (in 5), or a high dose (in 5) and in 2 children 9 and 14 years of age at the intermediate dose. At baseline, the median best corrected visual acuity in the study eye was 2.4 log 10 of the minimum angle of resolution (range, 3.9 to 0.6). No serious adverse events related to the treatment or procedure and no dose-limiting toxic effects were recorded. Six participants had a meaningful improvement from baseline in cone-mediated vision as assessed with the use of FST, of whom 5 had improvement in at least one other key secondary outcome. Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test. Six participants had a meaningful improvement from baseline in the vision-related quality-of-life score. Conclusions The safety profile and improvements in photoreceptor function after EDIT-101 treatment in this small phase 1–2 study support further research of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine and others; BRILLIANCE ClinicalTrials.gov number, NCT03872479 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The doses of AAV vectors that have been used in retinal gene therapy trials have ranged from ~1 × 10 8 (Heier et al., 2017) up to ~3 × 10 12 vg/eye (Yang et al., 2022; Pierce et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Pierce et al., 2024
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a groundbreaking first-in-human study, EDIT-101 (Editas, Cambridge, Massachusetts, USA), comprising an AAV5 vector encoding Staphylococcus aureus Cas9 and two guide RNAs targeting CEP290 associated with LCA, was well tolerated at relatively high vector doses (Pierce et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Pierce et al., 2024
In the citing paper
“In humans, EDIT-101 has demonstrated a positive safety profile and variable effectiveness of visual functional outcomes (retinal sensitivity, visual acuity, Ora–Visual Navigation Challenge) in Phase 1/2 of a small cohort of 14 participants ( NCT03872479 ), 64 which is ongoing with a larger cohort (34 participants) to confirm efficacy ( Table 1 ).”
From Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches (2025) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Mutations in the CEP290 (NPHP6) Gene Are a Frequent Cause of Leber Congenital Amaurosis
den Hollander, A. I., Koenekoop, R. K., Yzer, S., López, I., Arends, M. L., Voesenek, K., Zonneveld, M. N., Strom, T. M., Meitinger, T., Brunner, H. G., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/507318 · Cited by 669
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Self-citationWorldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
Self-citationParfitt, D. A., Lane, A., Ramsden, C. M., Carr, A. F., Munro, P., Jovanovic, K., Schwarz, N., Kanuga, N., Muthiah, M. N., Hull, S., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.03.021 · Cited by 314
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Csaky, K. G., Richman, E. A., & Ferris, F. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1132 · Cited by 265
Clinical Characteristics and Current Therapies for Inherited Retinal DegenerationsPreprint
Sahel, J., Marazova, K., & Audo, I. S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 249
Flagged first, then by citations
Research works printed but not linked: 1
- Pierce EA Ashimatey BS Jayasundera T et al. Twelve-month natural history study of CEP290-associated retinal degeneration. Ophthalmol Sci (in press) (https://www.ophthalmologyscience.org/article/S2666-9145(24)00019-8/pdf).
Cited by
Sorted by citations
Items 201–236 of 236
Liang, Y., Sun, X., Chen, H., Cui, Z., Li, W., Guo, Y., Chen, Y., Mao, S., Duan, C., Zhang, R., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102316
Tang, J. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202624001031
Gülkaş, S., Fenniri, I., Bruyn, H. D., Brown, A. M., Omorodion, J. O., Altschwager, P., & Fulton, A. B. (2026) · Ophthalmic Genetics · doi:10.1080/13816810.2026.2692063
Texeira, C. H. M., Rodrigues, G. D., Martins, E. A. D. S., Nunes, P. H. S., da Silva, L. M. P., Muccioli, C., Berezovsky, A., Ferraz, N. N., Sacai, P. Y., Salles, M. V., et al. (2026) · Ophthalmic Genetics · doi:10.1080/13816810.2026.2692066
Genetically enhanced mesenchymal stem cells for aging intervention
Jing-Hui, L. E. I., Guang-Hui, L. I. U., & Wang, S. (2026) · Shengming kexue · doi:10.3724/cbls.2026094
Xu, S., Geng, J., Xiong, W., Liu, M., Wang, C., Wang, X., Tang, T., Zhang, Q., Yuan, H., & Lu, Y. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02435-1
Amato, A., Iarossi, G., & Stephenson, K. A. J. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.07.039
CDHR1-associated retinal degeneration: Clinical phenotypes and therapeutic approaches
Narayan, A. R., Issa, P. C., Yusuf, I. H., & MacLaren, R. E. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101508
Zheng, N., Liang, J., Ouyang, T., Zhao, S., Yang, C., Zuo, Z., & He, C. (2026) · Small · doi:10.1002/smll.75176
Sriwidodo, S., Suhandi, C., Sagitasa, S., Davinali, B. A. A., Maksum, I. P., & Safuan, S. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100643
Macha, N. N., & Yu, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166492
Chandrasekaran, S., Duraisamy, N., Jagadeesan, M., Palukuri, Y. K., & Selvan, S. T. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103007
Shimokawa, S., Yamamoto, K., Hisai, T., Fukushima, M., Fujiwara, K., Koyanagi, Y., Notomi, S., Ishikawa, K., Tsukamoto, S., Hirata, A., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101381
Long, N., Si, M., Jiang, Y., Chen, F., Chen, B., Jiang, F., Pan, S., Chu, X., & Wu, H. (2026) · Frontiers in Medical Technology · doi:10.3389/fmedt.2026.1898982
Mesenchymal drift in ciliopathy iPSC-derived RPE reveals a convergent pathogenic cell state
Reichert, D., Gül, S., Ortolan, D., McGaughey, D. M., Montford, J., Ryu, J., Jeffrey, A. S., Lewallen, C. F., Veres, K., Villasmil, R., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117906
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
Biomaterials in Retinal Surgery: Engineering the Future
Dindar, I. A., Shoichet, M. S., Labriola, J. M., Forman, A., & Devenyi, R. G. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.08.039
Kaur, K., Chandel, S., & Singh, R. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100741
Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders
Bashir, K., Vasudev, P., Chhetri, V., Dubhashi, D. P., Teli, Y. G., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1868779
Precision in vitro tools for tissue engineering applications
Saran, M., Pareek, S., & Bagaria, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33455-9.00007-9
Esposito, F., Padmanabhan, A., Rhiel, M., Lupo, M., Marrocco, E., Auricchio, S., Cundin, X. B., Pellecchia, S., Cornu, T. I., Andrieux, G., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103047
Gene therapy for rare diseases: technological innovation and clinical translation
ZHANG, Y.-J., & Yuan, H. (2026) · Shengming kexue · doi:10.3724/cbls.2026132
Mahato, S., Daniele, E., Lewallen, C. F., Sharma, R., & Bharti, K. (2026) · Annual Review of Vision Science · doi:10.1146/annurev-vision-110725-100948
Mohanna, S. Z. M., Korecki, A. J., Kazemian, P., Lengyell, T. C., Adair, B. A., Leavitt, B. R., & Simpson, E. M. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1910209
Valenzano, R., Lu, X., Mulder, A. A., van Dijk, E. H. C., Koning, R. I., Gonçalves, M. A. F. V., & Wijnholds, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.14.751468
Hillen, A. E. J., Capuano, I., Gega, B., Norata, R., Mombled, M., Laface, I., Zambonini, G., Lomagno, A., Rouillon, M., Giannelli, S. G., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.019
Comorbid Auditory and Visual Dysfunction: From Pathogenic Genes to Gene Therapy
Hu, J., Kong, C., & Sun, Y. (2026) · Genes · doi:10.3390/genes17091149
Antioxidant Strategies for Inherited Retinal Degenerations in the Era of Gene Therapy
Yang, Y., Chen, Q., Zeng, J., Liang, L., Tao, Z., She, K., Ren, C., & Lu, F. (2026) · Antioxidants · doi:10.3390/antiox15101229
Wen, Z., & Su, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70764
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
The global patent landscape of CRISPR–Cas applications in medicine
Yu, Y., Zhang, Y., Xu, Y., Wen, C., Li, L., & Yu, T. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03337-4
Retinitis Pigmentosa: A Review of Its Pathogenesis and Emerging Molecular and Cellular Therapies
Tuli, N., Baeshen, M., Echbicheb, M., Kulbay, M., Ayalon, A., Ali, S. K., & Qian, C. X. (2026) · Vision · doi:10.3390/vision10040083
Mastering the eye: Clinical paradigm shifts from optical restoration to genomic correction
Zhang, X., Li, F., Huang, D., Yu‐Wai‐Man, P., Grzybowski, A. E., Aung, T., Lam, D. S. C., & Weinreb, R. N. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101537
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Weener, M. E., & Kotliar, K. E. (2026) · Cells · doi:10.3390/cells15211931
Metadata
- Authors
- Pierce, E. A., Aleman, T. S., Jayasundera, K. T., Ashimatey, B. S., Kim, K., Rashid, A., Jaskolka, M. C., Myers, R. L., Lam, B. L., Bailey, S. T., Comander, J. I., Lauer, A. K., Maguire, A. M., & Pennesi, M. E.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- From the Ocular Genomics Institute, Department of Ophthalmology, Mass Eye and Ear and Harvard Medical School, Boston (E.A.P., J.I.C.), and Editas Medicine, Cambridge (B.S.A., K.K., A.R., M.C.J., R.L.M.) — both in Massachusetts; the Scheie Eye Institute and the Division of Ophthalmology of the Children’s Hospital of Philadelphia, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (T.S.A., A.M.M.); the University of Michigan Kellogg Eye Center, Ann Arbor (K.T.J.); the Bascom Palmer Eye Institute, University of Miami, Miami (B.L.L.); and the Casey Eye Institute, Oregon Health and Science University, Portland (S.T.B., A.K.L., M.E.P.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-06-06
- Volume
- 390
- Issue
- 21
- Pages
- 1972-1984
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11389875
- OpenAlex
- W4396676517
- Cited by
- 237
- References
- 41
- Citations by year
- 2026: 101 · 2025: 103 · 2024: 33
- FWCI
- 31.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Malcolm M. Marquis MD Endowed Fund for Innovation
- Research to Prevent Blindness
- Irene Heinz Given and John La Porte Given Endowment
- Hope For Vision
- National Eye Institute (P30 EY010572, P30 EY014104)
- Editas Medicine
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- CRISPR/Cas9 genome editing, subretinal injection, photoreceptor function, best-corrected visual acuity, retinal sensitivity, vision-related quality of life, children, compound heterozygosity
- MeSH terms
- Gene Editing, Adolescent, Adult, Antigens, Neoplasm, Cytoskeletal Proteins, Female, Humans, Male, Middle Aged, Quality of Life, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Cell Cycle Proteins, Young Adult, Injections, Intraocular, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
